Lesson 7.2: Pneumonia and Respiratory Infections

Introduction

In this section, we will explore pneumonia and respiratory infections in detail, crucial topics for understanding common pulmonary diseases. The objectives include:

Defining community- and hospital-acquired pneumonia, bronchitis, and influenza.
Understanding severity scoring, site-of-care decisions, and empiric therapy.
Learning how to choose appropriate empiric therapy and site of care for respiratory infections.
Applying severity tools to admission and escalation decisions.
Explaining the main ideas and terminology related to pneumonia and respiratory infections.

To engage your interest, consider how pneumonia remains a significant health concern worldwide, contributing to morbidity and mortality, especially in vulnerable populations such as the elderly and those with chronic illnesses.

Section 1: Overview of Pneumonia and Respiratory Infections

1.1 Types of Pneumonia

Pneumonia is an infection that inflates the air sacs in one or both lungs, which can fill with fluid or pus, leading to cough with phlegm, fever, chills, and difficulty breathing. The two primary types of pneumonia are:

Community-Acquired Pneumonia (CAP): This type occurs in people who have not recently been hospitalized or had extensive medical care. Common pathogens include Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae.
Hospital-Acquired Pneumonia (HAP): This occurs 48 hours or more after admission to a hospital and was not present at the time of admission. Common pathogens include Pseudomonas aeruginosa and Staphylococcus aureus and tend to affect patients with weaker immune systems.

1.2 Bronchitis and Influenza

Bronchitis: An inflammation of the lining of the bronchial tubes, often caused by viruses. The main symptoms include cough, production of mucus, fatigue, and sometimes fever. Common causative agents may include influenza and coronavirus.
Influenza: A viral infection affecting the respiratory tract, leading to severe illness and sometimes death. Symptoms typically include fever, chills, cough, throat pain, and body aches.

Section 2: Severity Scoring and Site-of-Care Decisions

2.1 Severity Scoring Systems

Severity scoring tools help healthcare providers to assess the severity of pneumonia and make informed decisions regarding treatment and admission. Two commonly used tools are:

CURB-65 Score: This tool assesses five criteria: Confusion, Urea level > 7 mmol/L, Respiratory rate ≥ 30 breaths per minute, Blood pressure (systolic < 90 mmHg or diastolic ≤ 60 mmHg), and Age ≥ 65 years. Each criterion scores 1 point, with a total score guiding decision-making:
Score 0-1: Low Risk (consider outpatient treatment)
Score 2: Moderate Risk (consider inpatient treatment)
Score 3 or higher: High Risk (consider ICU admission)

Example of CURB-65 Calculation: A 70-year-old man presents confused, with a respiratory rate of 32, blood pressure of 88/58, and a BUN of 8 mg/dL. His CURB-65 score equals 3, indicating high risk.

Pneumonia Severity Index (PSI): A more comprehensive tool that incorporates additional factors, including liver and heart conditions to provide a more detailed risk assessment. The PSI categorizes patients into classes based on their score for tailored management options.

2.2 Site-of-Care Decisions

Determining the site of care is critical based on the severity of the pneumonia presentation:

Outpatient: For patients with low CURB-65 or PSI scores who are stable and without severe co-morbidities.
Inpatient (general ward): For those with moderate scores, requiring monitoring but not severely ill.
Intensive Care Unit (ICU): For high CURB-65 or PSI scores, respiratory failure, or septic shock.

Section 3: Empiric Therapy

3.1 Choosing Empiric Therapy

Empiric therapy refers to the initiation of treatment based on the most likely pathogens before laboratory results are available, essential for managing infections efficiently. The choice depends on risk factors, the type of pneumonia, and local guidelines.

For CAP in outpatient settings, typical first-line therapy includes:

Macrolides (e.g., azithromycin)
Tetracyclines (e.g., doxycycline)

For CAP in inpatient settings, the regimen may escalate to:

A respiratory fluoroquinolone or a combination of a beta-lactam and macrolide.

In HAP, empiric therapy often includes:

Piperacillin-tazobactam or cefepime and coverage for methicillin-resistant Staphylococcus aureus (MRSA) if indicated.

3.2 Follow-Up and Escalation

After starting empiric therapy, it is crucial to revisit the patient's response within 48-72 hours. Improved symptoms might lead to de-escalation or switching to oral therapy, whereas no improvement could necessitate broader spectrums or adjustments based on culture and sensitivity results.

Conclusion

Understanding pneumonia and respiratory infections is vital for effective diagnosis and management in various clinical scenarios. This lesson has covered the definitions and types of pneumonia, severity scoring, site-of-care decisions, and empiric therapy approaches. Proper application of this knowledge prepares you for addressing respiratory infections in diverse environments.

Study Notes

Community-acquired pneumonia occurs outside healthcare settings; hospital-acquired develops during hospital stays.
Use CURB-65 and PSI for assessing pneumonia severity and guiding treatment decisions.
Empiric therapy is initiated based on likely pathogens before lab results; adjust as necessary based on patient response.
Employ close monitoring for treatment implications and assess for escalation or de-escalation of care based on patient status.